Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Sells $1,206,004.59 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 27,279 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the sale, the chief executive officer now owns 138,641 shares of the company’s stock, valued at $6,129,318.61. The trade was a 16.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Christopher Peetz also recently made the following trade(s):

• On Monday, February 3rd, Christopher Peetz sold 9,102 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44.
• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total value of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $320,678.98.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $47.13 on Thursday. The stock has a 50 day moving average of $47.65 and a 200 day moving average of $43.62. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of -23.33 and a beta of 1.04. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The business had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. As a group, sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp raised its holdings in shares of Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after purchasing an additional 297,511 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Mirum Pharmaceuticals by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock valued at $12,798,000 after buying an additional 17,149 shares during the period. Geode Capital Management LLC lifted its position in shares of Mirum Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after buying an additional 29,017 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Mirum Pharmaceuticals by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock worth $6,021,000 after acquiring an additional 29,545 shares during the period. Finally, Golden State Equity Partners increased its holdings in Mirum Pharmaceuticals by 1,390.8% in the 4th quarter. Golden State Equity Partners now owns 19,380 shares of the company’s stock worth $801,000 after acquiring an additional 18,080 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. HC Wainwright increased their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.